An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

Explore CRISPR technology explained, gene editing science, DNA modification, and genetic engineering ethics—discover how ...

One dose of an experimental drug cover offer lifetime treatment for people with high cholesterol, but its long-term safety is ...

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex ...

A cutting-edge medical experiment in a small trial has demonstrated the effectiveness of a one-time CRISPR gene editing treatment in lowering cholesterol levels ...

The Cambridge-based biotech company is studying the use of Crispr, the Nobel Prize-winning gene-editing technology, to treat ...

Pioneering CRISPR trial shows single infusion permanently lowers bad cholesterol by 50% in patients who don't respond to medication.

A new study has revealed that the gene HMGN1 is a key driver of congenital heart defects (CHDs) in Down syndrome. Using ...

Pairwise has licensed its Fulcrum® gene editing platform to the International Rice Research Institute (IRRI), a non-profit agricultural research organization. The agreement will enable IRRI to apply ...

CRISPR excites ambition. Just consider a few CRISPR applications: gene drives (showing promise as a way to prevent malaria); ex vivo and in vivo gene therapies (entering clinical trials); and ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $55.16, demonstrating a -2.56% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily ...